Category Specific RSS

Thomas Cox

Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%

Each year, more than 4,000 Australians are diagnosed with pancreatic cancer, a form of cancer which is difficult to diagnose…

2 years ago

Momentum continues for Pharmaxis with $1.4m in grants following oversubscribed raise

Just days after closing their oversubscribed $9.8 million capital raise, drug developer Pharmaxis (ASX: PXS) has seen further funding devoted…

4 years ago